A new chapter in treating type 2 diabetes may be on the horizon as AstraZeneca introduces an oral GLP-1 pill, potentially moving diabetes and obesity treatment away from injections. For individuals living with type 2 diabetes or struggling with weight, the challenge involves not only blood sugar management but also stubborn pounds that complicate health. Injectable GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have revolutionized diabetes care, aiding weight loss and improving blood sugar control. However, many people find injections inconvenient or uncomfortable. AstraZeneca now believes it has developed an effective pill alternative.
What Is Elecoglipron?
Elecoglipron is an oral GLP-1 receptor agonist that AstraZeneca acquired from the Chinese biotechnology company Eccogene last year. GLP-1 medications mimic a gut hormone that curbs appetite, slows digestion, boosts insulin production, and regulates blood sugar. This dual action makes them effective for both weight loss and diabetes management. While most leading GLP-1 drugs are injectable, researchers have long pursued an oral version because tablets are easier to take and more acceptable to patients. If successful, elecoglipron could compete with established players like Novo Nordisk and Eli Lilly.
Weight Loss Results
In the phase IIb VISTA trial, adults with obesity or excess weight taking higher doses of elecoglipron lost approximately 10.5% of their body weight within 26 weeks. Some participants continued losing weight, achieving up to 11.8% reduction at 36 weeks. Nearly 90% of those on the highest dose lost at least 5% of their body weight, a threshold considered clinically significant. For a person weighing 100 kilograms, this translates to a loss of over 10 kilograms. These results are notable because oral medications typically have lower bioavailability than injectables, yet elecoglipron is closing the efficacy gap.
Diabetes Outcomes
The SOLSTICE trial focused on individuals with type 2 diabetes, a condition where the body either resists insulin or produces insufficient amounts, leading to elevated blood sugar and potential complications. Elecoglipron not only lowered blood sugar but also resulted in an average weight loss of 7.7% over 26 weeks at higher doses. Additionally, participants showed improvements in cardiovascular and metabolic risk factors. GLP-1 drugs address underlying issues such as weight, heart risk, and kidney problems, offering broader health benefits beyond glucose control.
Side Effects
Like other GLP-1 medications, elecoglipron caused gastrointestinal side effects including nausea, vomiting, constipation, and stomach discomfort. However, these were mostly mild to moderate, and discontinuation rates due to side effects were low. No significant liver safety concerns were reported. While an ideal weight-loss pill without gastrointestinal issues remains elusive, elecoglipron's side effect profile is comparable to existing treatments.
Comparison with Existing Drugs
Elecoglipron's average weight loss of 10.5% positions it among the top oral medications, though it falls short of some injectable counterparts like Wegovy, which achieves 14% or more, and newer Eli Lilly drugs. The primary advantage of elecoglipron is its oral administration—a simple daily pill. If future trials confirm its safety and efficacy, many patients and healthcare providers may prefer this convenient option, potentially expanding access to GLP-1 therapies.
Next Steps
Following promising phase II results, AstraZeneca plans to initiate larger phase III studies to evaluate elecoglipron in broader populations and assess long-term safety. Regulatory approval will depend on these outcomes. Given rising rates of diabetes and obesity worldwide, effective and easy-to-administer treatments are increasingly important. If these results are sustained, elecoglipron could represent a significant shift, offering effective weight loss and diabetes control without the need for injections. For individuals managing diabetes daily, this development offers both hope and convenience.
